Analysts forecast that Protagonist Therapeutics Inc (NASDAQ:PTGX) will post ($0.41) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Protagonist Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.69) and the highest estimate coming in at ($0.12). Protagonist Therapeutics posted earnings per share of ($0.29) during the same quarter last year, which indicates a negative year over year growth rate of 41.4%. The firm is expected to report its next earnings results on Monday, November 5th.
According to Zacks, analysts expect that Protagonist Therapeutics will report full-year earnings of ($1.01) per share for the current year, with EPS estimates ranging from ($1.28) to ($0.73). For the next fiscal year, analysts forecast that the firm will post earnings of ($1.75) per share, with EPS estimates ranging from ($2.20) to ($1.29). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Protagonist Therapeutics.
Protagonist Therapeutics (NASDAQ:PTGX) last issued its earnings results on Tuesday, August 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.07). Protagonist Therapeutics had a negative net margin of 56.92% and a negative return on equity of 24.16%. The company had revenue of $11.67 million for the quarter, compared to analysts’ expectations of $8.55 million.
In other news, Director Bryan Giraudo purchased 10,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Wednesday, May 16th. The shares were acquired at an average price of $6.46 per share, for a total transaction of $64,600.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $64,600. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder X L.P. Canaan sold 77,591 shares of the stock in a transaction that occurred on Monday, May 14th. The stock was sold at an average price of $6.37, for a total transaction of $494,254.67. The disclosure for this sale can be found here. 13.80% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC boosted its position in Protagonist Therapeutics by 255.0% in the first quarter. Cubist Systematic Strategies LLC now owns 11,593 shares of the company’s stock valued at $100,000 after buying an additional 8,327 shares in the last quarter. Prudential Financial Inc. acquired a new stake in Protagonist Therapeutics in the first quarter valued at approximately $116,000. Two Sigma Advisers LP acquired a new stake in Protagonist Therapeutics in the fourth quarter valued at approximately $362,000. Element Capital Management LLC acquired a new stake in Protagonist Therapeutics in the first quarter valued at approximately $175,000. Finally, Teachers Advisors LLC boosted its position in Protagonist Therapeutics by 33.1% in the fourth quarter. Teachers Advisors LLC now owns 21,593 shares of the company’s stock valued at $449,000 after buying an additional 5,375 shares in the last quarter. Institutional investors and hedge funds own 57.16% of the company’s stock.
NASDAQ:PTGX traded down $0.85 during mid-day trading on Tuesday, reaching $10.41. The company’s stock had a trading volume of 285,715 shares, compared to its average volume of 505,646. The firm has a market cap of $238.92 million, a PE ratio of -4.98 and a beta of 3.18. Protagonist Therapeutics has a 1 year low of $5.50 and a 1 year high of $23.97.
Protagonist Therapeutics Company Profile
Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis.
Recommended Story: Trading Strategy Methods and Types
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.